Twin City Private Wealth LLC Has $1.56 Million Holdings in GSK plc (NYSE:GSK)

Twin City Private Wealth LLC lifted its holdings in shares of GSK plc (NYSE:GSK) by 13.4% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 45,760 shares of the pharmaceutical company’s stock after buying an additional 5,417 shares during the period. GSK makes up about 1.4% of Twin City Private Wealth LLC’s holdings, making the stock its 27th largest holding. Twin City Private Wealth LLC’s holdings in GSK were worth $1,563,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of GSK. United Bank boosted its stake in shares of GSK by 7.3% during the 3rd quarter. United Bank now owns 25,785 shares of the pharmaceutical company’s stock worth $1,054,000 after buying an additional 1,760 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in shares of GSK by 3.4% during the 3rd quarter. Thrivent Financial for Lutherans now owns 53,348 shares of the pharmaceutical company’s stock worth $2,181,000 after buying an additional 1,737 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of GSK by 13.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 121,603 shares of the pharmaceutical company’s stock worth $4,971,000 after buying an additional 14,687 shares during the last quarter. Raymond James Trust N.A. boosted its stake in shares of GSK by 6.9% during the 3rd quarter. Raymond James Trust N.A. now owns 45,948 shares of the pharmaceutical company’s stock worth $1,878,000 after buying an additional 2,969 shares during the last quarter. Finally, Nwam LLC acquired a new position in shares of GSK during the 3rd quarter worth about $625,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

GSK has been the subject of a number of recent research reports. Morgan Stanley assumed coverage on shares of GSK in a research note on Wednesday, February 12th. They set an “equal weight” rating for the company. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Seven research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Stock Down 0.5 %

Shares of GSK stock opened at $39.22 on Monday. The stock has a market cap of $81.18 billion, a price-to-earnings ratio of 24.67, a PEG ratio of 1.12 and a beta of 0.58. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.93. The firm’s 50-day moving average is $36.66 and its 200-day moving average is $36.87.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Sell-side analysts predict that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be issued a $0.3932 dividend. This is a boost from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a yield of 4.01%. The ex-dividend date of this dividend is Friday, February 21st. GSK’s dividend payout ratio is currently 98.74%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.